# Assisted Reproductive Technology Dataset of Embryo Time-lapse Images and Clinical Data

Dmytro Zhylko<sup>a,\*</sup>, Raquel Del Gallego<sup>b,\*</sup>, Sarah Pardo<sup>a</sup>, Rameen Mahmoud<sup>a</sup>, Ya Tung Hsieh<sup>a</sup>, Salma Selim<sup>b</sup>, Daniela Nogueira<sup>b</sup>, Ibrahim El-Khatib<sup>b</sup>, Barbara Lawrenz<sup>b</sup>, Human M. Fatemi<sup>b</sup>, and Farah E. Shamout<sup>a</sup>

<sup>a</sup>Engineering Division, NYU Abu Dhabi; <sup>b</sup>ART Fertility Clinics; <sup>\*</sup>Co-first authors.

In this report, we present Version 1.0 of the Assisted Reproductive Technology (ART) Dataset, a multi-modal fertility dataset from treatments performed at the ART Fertility Clinic in Abu Dhabi, United Arab Emirates, between 2015 and 2022. The data consists of Electronic Health Records (EHR) and embryo development image sequences captured with the Vitrolife EmbryoScope time-lapse system, providing detailed treatment, morphology, and pregnancy outcome information. The final processed dataset consists of a total of 14,776 embryos from 1,810 patients across 2,500 treatments. This dataset will be used in the development of machine learning models for automated analysis of embryo development and viability, to assist clinical decision-making. This report provides a summary of the statistics of the dataset, as well as the extraction and pre-processing pipelines of the time-lapse images and EHR data. The dataset is private, so we publish this report for transparency on data pre-processing pipelines to share the methodology with similar studies that may arise.

## 1. Introduction

Assisted Reproductive Technology (ART) refers to medical treatments and procedures designed to assist individuals experiencing difficulties in achieving spontaneous pregnancy conception. Infertility is estimated to affect 15% of the global population, over 48 million couples worldwide (1, 2). However, each treatment cycle has a high financial, physical, and emotional cost. This motivates ongoing research to achieve higher success rates by optimizing treatment protocols. Embryo selection is a critical step in ART cycles, and early, accurate assessment of embryo viability can dramatically impact treatment outcomes. Historically, embryo evaluation has been performed through microscopic assessment at specific time points, disturbing the embryo's controlled incubation environment. Thanks to the introduction of time-lapse imaging systems, designed with built-in cameras, embryologists have been able to monitor development with unaltered conditions. Despite the controversy surrounding whether time-lapse technology has a real impact on clinical outcomes (3), the high-resolution data produced is key for use in developing computational learning models.

In this report, we present the Assisted Reproductive Technology (ART) Dataset, which contains data from 14,776 embryos cultured at the ART Fertility Clinic in Abu Dhabi, United Arab Emirates, between 2015 and 2022. Each embryo has a time-lapse image sequence captured during its development in the Vitrolife EmbryoScope time-lapse system<sup>\*</sup>, combined with Electronic Health Records (EHR) of information about the patient and treatment protocol. In Section 2, we present a summary of the contents of the final processed dataset and provide the statistics of its features and labels. In Section 3, we describe the pre-processing pipelines used to extract and clean the raw images and records sourced from the clinic.

## 2. Overview

**2.A. Overall statistics.** The final dataset contains 14,776 multimodal samples of combined embryo EHR and time-lapse image sequences, collected from 1,810 patients across 2,500 treatment cycles. A treatment cycle refers to a single round of oocyte pick-up and artificial fertilization, as a consequence of the administration of a supplementary hormonal treatment to stimulate ovarian oocyte growth. Patient age ranges from 19 to 53, with an average age of 34.7. The average number of treatment cycles per patient is 1.3 (min. 1, max. 17), and the average number of embryos per treatment cycle is 5.9 (min. 1, max. 12). 13,816 embryos were fertilized from fresh oocytes, and 960 were from frozen oocytes. 13,388 were fertilized using Intra-Cytoplasmic Sperm Injection (ICSI), 91 were fertilized using next-day ICSI, while 1,297 were fertilized using traditional in-vitro fertilization (IVF).

Since next-day ICSI is not a standard practice in every clinic, we introduce it briefly. In next-day ICSI, initially immature oocytes develop to mature oocytes after one day in culture, and then they are fertilized with the ICSI technique.

We further analyze cohort characteristics and provide statistics and descriptions in Table 8. We derive several datasets from the initial extraction, following the tasks defined in Section 2.B, and provide sub-dataset sizes in units of single embryo in Tables 3, 2, 5, 6.

**2.B.** Datasets and labels. In our final labeled datasets, multiple labels are associated with each embryo, allowing for a variety of learning tasks. Clinic protocols determine the type of labels and properties which are available in a given dataset. The main outcomes are described in Table 1. We present the statistics and descriptions of the primary label sets of the ART Embryo Dataset: sequence-level blastocyst development labels (Section 2.B.1), image-level development stage labels (Section 2.B.2), sequence-level genetic labels based on biopsy results (Section 2.B.3), and sequence-level pregnancy outcomes (Section 2.B.4).

For the development of deep neural networks, we group the embryo sequences based on the patient identifier, and assign each patient randomly to either the training (60%), validation (20%), or test (20%) set, ensuring that all embryos from a unique patient are present in only one split. We then filter each data split for each task to ensure no overlap across training and test sets across all tasks. This limits amount of patient specific learned features (like patient embedding) we can use, since test time patients are not present in training set, but

\*To whom correspondence should be addressed. E-mails: farah.shamout@nyu.edu.

<sup>\*</sup> https://www.vitrolife.com/products/time-lapse-systems/embryoscope-8-time-lapse-system/

Table 1.	Definitions o	f outcome	labels assi	igned to	each embryo.

Name	Definition	
Blastocyst formation	Positive if embryo reached any stage	
	of blastulation (tSB, tB, tEB, tHB).	
Ploidy	Positive (euploid) if biopsied embryo tissue	
	shows 23 chromosome pairs.	
Gestation	Positive if a gestational sac is detected.	
Heartbeat	Positive if a fetal heartbeat is detected.	
Live birth	Positive if the pregnancy successfully	
	develops to live birth.	

Table 2. Blastocyst label distributions for each dataset split.

Label	Train	Validation	Test
Positive	5,860	2,082	2,021
Negative	3,059	885	869

prevents any potential data leak and tests model robustness to potential distribution shifts.

2.B.1. Sequence-level blastocyst formation. Blastocyst development is subdivided into several stages: start of blastulation (tSB), blastocyst formation (tB), expanded blastocyst (tEB), and hatched blastocyst (tHB). Fig. 2 shows examples of each step in blastocyst development. We considered the presence of any of these labels as a positive blastocyst formation. We assign a positive label to all sequences which have at least one blastocyst label assigned to any image, in case no such label is present, or labels are missing entirely, we cross reference image annotations with EHR data, that contains less accurate indication, like day blastocyst stage was reached. If any of the aformentioned conditions are meet we assign positive label to this sequence, and negative otherwise. While in some cases an embryo may develop to blastocyst but degenerate before it can be preserved or transferred, we consider these to be positive labels for the blastocyst prediction task, and we trim the sequence up to the positive blastocyst stage or day before degeneration, depending on which one is present. The distributions of positive and negative samples in the training, validation and test sets are provided in Table 2. Dataset contains 7,043,561 images, across 14,776 embryo sequences, collected from 1,810 different patients, and is the biggest dataset we extracted.

2.B.2. Image-level development stage. The EmbryoScope system enables embryologists to label images in a sequence with the observed stage of development, with a total of 18 possible stages. The definition of each development stage is provided in Table 3. Our annotations contain cell division stage annotations up to 9 cells, followed by the compaction and blastulation stages. The final dataset contains 6,677,028 labeled images from 1,798 embryo sequences, collected from 1,798 patients. We filter sequences where we suspect incomplete annotation might have occurred, as a result this dataset contains only 17 stages, as we identified sequences with tDead stage as sequences with risk of incomplete annotation. For the full explanation of filtering rules refer to Section 4.A. Table 3 shows the label distributions for training, validation, and test sets. No monotonicity in distributions indicate, that not all of the stage annotations are present in sequence, even if sequence progressed past certain stage. This is the result of interval-based image acquisition, that results in certain stages happening in between captures, especially ones that happen fast, e.g. odd cell count stages.




Fig. 1. Microscopy images of embryos with corresponding developemnt stage labels.

Table 3. Definitions of development stage labels assigned to individual images and the stage label distributions for each dataset split.

Stage	Definition	Train	Validation	Test
tPB2	second polar body appearance	7,202	2,402	2,320
tPNa	pronuclei appearance	7,270	2,445	2,388
tPNf	pronuclei fading	7,778	2,540	2,564
t2	second cell appears	7,787	2,562	2,563
t3	third cell appears	5,720	1,920	1,914
t4	fourth cell appears	7,356	2,425	2,417
t5	fifth cell appears	6,471	2,179	2,173
t6	sixth cell appears	6,599	2,177	2,169
t7	seventh cell appears	6,330	2,099	2,016
t8	eight cell appears	6,608	2,170	2,142
t9	ninth cell appears	6,161	2,033	2,010
tSC	start of compaction	5,846	1,955	1,883
tM	morula formation	6,062	1,982	1,982
tSB	blastulation start	5,788	1,894	1,905
tB	blastocyst formation	4,670	1,500	1,498
tEB	blastocyst expansion	3,391	1,019	1,092
tHB	blastocyst hatching	1,357	425	405

Additionally, labels might have been missed, due to later well insertion during IVF or next day ICSI protocols, resulting in missed first stages. Considering practical aspect of this dataset, we in Table 4 also report distributions in the sub-sets after label filling, realized as forward filling of the annotations, by assigning previous label to current frame, unless label was already assigned in annotation. We can observe that some stages last significantly shorter then others, which contributes to unbalanced training problem. Fig. 1 shows an example of several embryo images with corresponding label.

Table 4. Definitions of development stage labels assigned to individual images and the stage label distributions for each dataset split after label filling.

. J.				
	Stage	Train	Validation	Test
	tPB2	143,672	49,606	43,588
	tPNa	442,490	152167	145529
	tPNf	106,368	34,275	34,170
	t2	310,770	109,461	102,951
	t3	124,918	41,900	48,357
	t4	339,530	116,512	116,989
	t5	178,569	56,188	65,932
	t6	190,754	60,561	67,462
	t7	198,372	69,732	65,237
	t8	325,070	106,228	103,975
	t9	384,439	126,038	131,670
	tSC	256,064	87,799	77,832
	tM	292,678	94,784	92,020
	tSB	351,187	119,055	122,939
	tB	152,144	52,421	48,278
	tEB	147,833	44,740	52,145
	tHB	56,711	17,787	17,131

**2.B.3.** Sequence-level ploidy outcomes. Our dataset includes results from PGT for an euploidy (PGT-A), which detects the



Fig. 2. Examples of embryos in different stages of blastocyst formation.

Table 5. Ploidy label distributions for each dataset split.

Label	Train	Validation	Test
Euploidy	2,091	800	762
Aneuploidy	2,521	862	836

number of chromosomes in the embryo cell nuclei (ploidy) to screen for chromosome abnormalities. The ART Dataset uses positive (euploid) and negative (aneuploid) PGT-A results to assign genetic outcome labels to each embryo sequence. In the final dataset, of the 7,872 embryos present in subset from Section 2.B.1, which additionally underwent conclusive genetic testing, 3,653 embryos were identified as euploid, where cells in the biopsy sample contain 23 chromosome pairs, and 4,219 embryos were identified as an euploid, where the cells contain an abnormal number of chromosomes. Embryos with inconclusive test result were removed from dataset (not included in above numbers). The aneuploid embryos are further categorized by an euploidy type: complex 1,824 (effects more then one chromosome), segmental 790 (gain/loss of chromosome segment), mosaic 336 (MVA syndrome), whole chromosome 3,495 (gain/loss of one whole chromosome), or triploid 5 (additional pair of chromosomes). The distributions of euploid and aneuploid labels in the training, validation, and test sets are provided in Table 5.

**2.B.4. Sequence-level pregnancy outcomes.** In the final dataset, 1,680 embryos were transferred to patients for pregnancy. Pregnancy outcome labels are subdivided by each survival stage: implantation, gestational sac, heartbeat and live birth. An unknown outcome refers to cases where a double embryo transfer is performed but only a single embryo progresses with the pregnancy, so that it is impossible to identify which of the two embryos survived. In total, 903 embryos have a positive implantation label, 557 negative, 220 unknown; 842 embryos had a gestational sac detected, 686 negative, 152 unknown; 757 had fetal heartbeat detected, 795 negative, 128 unknown; and 673 ultimately resulted in live birth 896 negative, 111 unknown. The distribution of pregnancy outcome labels is illustrated in Table 6.

## 3. Data collection and processing

The dataset consists of image sequences exported from the EmbryoScope time-lapse system and medical records retrieved from the clinic proprietary record software. Image preprocessing includes reading raw data, detecting unusable images using a convolutional neural network classifier, joining images with developmental stage and hour past insemination metadata, and writing sequences to hdf5 (4) format file, as described in Section 3.A. EHR pre-processing includes exporting tabular data from the clinic's proprietary record-keeping

#### Table 6. Pregnancy label distributions for each dataset split.

Task	Label	Train	Validation	Test
Implantation	Positive	524	193	186
	Negative	318	123	116
	Unknown	128	51	41
Gestational sac	Positive	489	180	173
	Negative	392	157	137
	Unknown	89	30	33
Fetal heartbeat	Positive	441	165	151
	Negative	454	180	161
	Unknown	75	22	31
Live birth	Positive	390	147	136
	Negative	516	198	182
	Unknown	64	22	25

Table 7. Metadata that is extracted from EmbryoScope data and stored with the final hdf5 files.

Metadata	Description
'patient_id'	Sequence-level patient identifier
'well_id'	Sequence-level well identifier
'cum_seq_len'	Sequence-level cumulative sequence length
'run'	Image-level frame number
'hpi'	Image-level hours post insemination
'stage'	Image-level embryo stage from annotations (with
	label filling)
'stage_no_fill'	Image-level embryo stage from annotations (without
	label filling)
'image_label'	Image-level blastocyst indicator (derived from 'stage')
'images'	Image at respective run
'is_well_full'	Image-level binary flag (used for filtering)
'sequence_label'	Sequence-level label indicating if sequence reached
	blastulation (for convenience)
other EHR features	Sequence-level values individually described in Ta-
	ble 8

software, applying basic type conversion and cleaning for consistency in manually-entered columns, and saving a subset of columns, to produce clean medical record features and outcome labels. Further details are described in Section 3.B. In this section we use word dataset in context of hdf5 files, to refer to 'column' of data. This is deliberate choice, to use language consistent with hdf5 documentation. We use "split(s)" to indicate subset of particular file with examples dedicated for either: training, validation or test purposes.

**3.A. EmbryoScope data.** The EmbryoScope device contains a Hoffman Modulation Contrast (HMC) microscope to capture images of individual embryos. Images are acquired every 10-15 minutes. At each round of acquisition, also referred to as "run", the embryo is imaged at 7 focal planes with an increment of 15 micrometers. The embryo is contained in a conical well. The average number of runs per file after filtering is 499.3 (min. 273, max. 835). Which after filtering

(see Section 4) corresponds to 476.7 (min. 128, max. 824) frames per sequence. Raw EmbryoScope data can be exported as SQL database files, which is the format retrieved for our dataset. This includes one image database file for each slide of embryos, as well as two databases of metadata: (i) patient information (PatientDB.fdb), and (ii) user annotations and machine environment properties (MainDB.fdb).

Within the image database files, an individual embryo is identified by combination of slide identifier and well number within the slide, and each image database file includes up to 12 embryos from the same treatment. Each file has a GENERAL table, with metadata such as time of insertion and measurements of the well environment, and an IMAGES table for the image sequences, where each row corresponds to a single monochromatic image of  $500 \times 500$  pixels in the format of a byte string which decodes to an image file. The images are indexed by (well number, run number, focal plane) and are associated with a raw time stamp of when the image was captured.

The initial image extraction consists of reading the image byte strings from the database files. In particular, the extraction procedure queries each database file for the IMAGES table, excluding calibration runs identified by run number < 1. We extract and save only the center focal plane of each imaging run, and we resize images to  $250 \times 250$  pixels to save the disc space and reduce data loading and computational costs. Eventually, during training images are usually resized or cropped to  $224 \times 224$ , so we leave extra pixels for augmentation purposes. We store sequences in combined hdf5 chunked dataset, with chunk size equal to single image dimensions. To address individual images or sequences, we additionally store cumulative sums of sequence length in separate hdf5 dataset in the same file. We opt for single tensor solution for ease of management implied by uniform access pattern between different types of time series columns and little overhead, but may consider splitting sequences into separate datasets once read latency becomes a limiting factor. For all sequences, the time stamp of the first run corresponds to the approximate time of insemination, so we convert the time stamp to hours post insemination ("hpi") and save it as dataset in the same hdf5 as the rest of data, with single vector format corresponding to images. For each well, we also retrieve development stage annotations from the MainDB.fdb file, join them with images using the raw time stamp, and save the annotations as corresponding vector of stage ids in the hdf5 dataset. It's important to note that, at times, multiple annotations (usually two) may be assigned to a single image. This typically occurs when a stage transition happens between acquisition intervals. In cases of such annotation overlap, we resolve the conflict by favoring the more advanced stage. This approach may lead to inaccurate single-frame annotations for stages captured in just one frame, or errors where the more advanced stage is assigned to the frame preceding an unseen stage transition, rather than the one following it. However, we opt for simpler conflict resolution scheme considering total number of collisions is small: 47 individual collisions in final dataset. We then filter the images for valid quality as detailed in Section 4. In addition, we augment the hdf5 dataset with features and labels from the EHR. Each feature is individually stored as separate dataset with the sequence order. The final output is an hdf5 file containing image data, image-level metadata, and

sequence-level features and labels for each embryo. Layouts and descriptions of derived and untypical columns can be found in Table 7. This overall image extraction is performed on the complete set of embryo ids which are valid according to the overall EHR filtering described in Section 4.A. We subsequently save a three different hdf5 files for each prediction task dataset. We split each dataset into train, validation and test set, with prior modification, by removing embryos which are filtered by task-specific criteria and augmented by data available only after certain point, like pre-transfer stimulation is only added to pregnancy outcomes prediction dataset (Section 2.B.4). We derive ploidy splits by individually filtering blastocyst formation splits, to ensure same patients are present in both datasets and models can be trained in multi-task fashion, or transferred from one task to another without data leak. Similarly pregnancy outcome splits are derived by filtering ploidy splits. Note: image-level development stage prediction dataset (Section 2.B.2) is split independently.

**3.B. Clinical data.** The clinical EHR data is accessed through a proprietary software API and can be exported as commaseparated values (CSV) file. It includes properties related to patient etiology, oocytes, ovarian stimulation, sperm measurements, endometrial preparation, and transfer, as well as the outcome labels described in Section 2.B. Table 8 provides a full list of the EHR features available, their definitions, and their possible values. For our prediction tasks, we focus on subsets of the full EHR features:

- **Patient etiology:** age, age of partner, demographics, hormonal measurements, antral follicle count (AFC), BMI, lifestyle factors (like smoking), medical, obstetric, and surgical histories.
- Ovarian stimulation data: ovarian stimulation protocol, stimulation priming, hormonal measurements, outcome measures (total oocytes and mature oocytes collected).
- **Oocyte data:** includes early or late oocyte maturation, whether the oocyte was cryopreserved, and fertilization method.
- Genetic properties: biopsy conclusiveness and subcategories of aneuploidy and monogenic disorder.
- **Sperm quality** sperm motility and concentration measurements before and after treatment
- Endometrial preparation data: endometrial preparation protocol, patient characteristics at transfer.
- **Transfer data:** number of embryos transferred, whether the embryo was transferred fresh or after cryopreservation, embryo age at time of transfer, in number of days, and transfer difficulty.

## 4. Filtering

We filter samples based on both image sequences and EHR data. In Section 4.A, we describe the filtering procedure with the associated statistics at each step. In Section 4.B, we describe the process of training an image classifier to detect empty images and images with excessive artifacts.

**4.A.** Application of inclusion and exclusion criteria. The raw EHR record initially contains 40,392 (2,206 patients, 3,366 treatments) embryos with ART identifiers. We filtered this

Туре	Name	Description	Values
PATIENT	Age (patient)	Patient age at oocyte pickup	min. 19, max. 53, mean 34.7
	BMI (patient)	BMI of patient	min. 13.4, max. 43.3, mean 27.1
	Age (partner)	Age of partner	min. 22, max. 83, mean 38.0
	BMI (partner)	BMI of partner	min. 16.2, max. 66.4, mean 29.1
	Smoking (patient)	Smoker status of patient	yes 598, occasional 58, no 13000, ex-smoker 55, unknown 1065
	Smoking (partner)	Smoker status of partner	yes 2870, occasional 60, no 891, ex-smoker 20, unknown 10935
	Nationality (patient)	Patient nationality	unique 111
	Nationality (partner)	Partner nationality	unique 88
	Parental cosanguinity (patient)	Cosanguinity present in patient's parents	yes 3536, no 11240
	Parental cosanguinity (partner)	Cosanguinity present in partner's parents	yes 3184, no 11592
	Couple cosanguinity	Cosanguinity present in couple	yes 3807, no 10969
	Menstrual cycle regularity	Presence of irregularity in patient's cycle	yes 2161, no 11925, unknown 690
	Ovary (right)	Abnormality in right ovary	yes 53, no 14723
	Ovary (left)	Abnormality in left ovary	yes 142, no 14634
	Ovarian pathology (right)	Type of abnormality in right ovary	polycystic 561, cyst 447, atrophic 73, multifollicular 29, hyperstimulated 6, n 13660
	Ovarian pathology (left)	Type of abnormality in right ovary	polycystic 505, cyst 625, atrophic 76, multifollicular 44, hyperstimulated 6, no
	Uterine cavity	Abnormality observed in uterine cavity	13520 unknown 14493, no 283
	Uterine malformation	Structural abnormality of uterus	yes 79, no 14697
	Uterus type	Phenotype of uterus	normal 9575, abnormal 899, unknown 4302
	Ishtmocele		
	ISNIMOCÉIÉ	Scarring present from a previous Cesarean section	yes 365, no 9854, unknown 4557
STIMULATION	Total COC collected	Number of oocytes collected	min. 1, max. 74, mean 16.7
	MII Count	Count of mature oocytes	min. 0, max. 58, mean 13.4
	Protocol	Stimulation medication	unknown 1673, Antagonist + Letrozole 5, Antagonist fixed day 5 11597, Antagonist
	11010001	Sumblation medication	
			flexible 332, Long agonist day 21 (subcutaneous) 13, Long agonist day 21 (spray
			638, Luteal phase stimulation 418, Minimal stimulation 17, Shangai Protocol 37
			Short agonist day 1 (subcutaneous) 8, Short agonist day 1 (spray) 19, Taymou
			Protocol 19
	E2 at trigger	Estradiol measurement at oocyte maturation date	min. 90.2, max. 7209, mean 2560.7
	P4 at trigger	Progesterone measurement at oocyte maturation date	min. 0.1, max. 22.8, mean 1.1
	AFC (left)	Antral follicle count in left ovary	min. 0, max. 30, mean 8.0
	AFC (right)	Antral follicle count in right ovary	min. 0, max. 30, mean 8.2
	AFC (total)	Antral follicle count in left ovary	min. 1, max. 60, mean 16.2
	AMH	Anti-Mullerian hormone measurement	min. 0.01, max. 23, mean 3.6
	OCP priming	Stimulation priming using oral contraceptive pills	yes 2283, no 12493
	E2 Priming	Stimulation priming using estradiol	yes 429, no 14347
DOCYTE	Oocyte status	Source of oocyte	fresh 13816, frozen 960
	Maturity 1	Oocyte maturity at first assessment	metaphase II 14685, metaphase I 51, germinal vesicle (GV) breakdown 39, Empt
			zona 1
	Technique	Fertilization technique	Classic IVF 1297, ICSI 13388, Next-day ICSI 91
	Degree of expansion	Clinician assessment of embryo expansion on last day of grows	BI1-BI8 8197, C1-C2 28, cells 18, degenerated or unknown 6533
ENETIC	PGT-M result	Result of monogenic disorder test (from ploidy prediction subset)	affected 277, affected transferable 8, unaffected 146, carrier 304, non-conclusive
			15, not performed 7122
PERM	Semen source	Method of semen collection	Fresh/frozen ejaculation 12386/439, Fresh/frozen TESA 508/36, Fresh/frozen
			TESE 100/57, Fresh/frozen micro TESE 95/151, Retrograde ejaculation 2
	Volume (ml) Initial	Initial volume of semen sample (excluding zeros from TESA, etc.)	min. 0.1, max. 10.5, mean 2.7
	Initial Concentration (M/ml)	Initial concentration of sperm in semen sample (excluding zeros)	min. 0.005, max. 449, mean 62.0
	Initial % Progessive	Initial percentage of progressive sperm in semen sample (excluding zeros)	min. 1, max. 94, mean 43.7
	Initial % NonProgressive	Initial percentage of progressive sperm in semen sample (excluding zeros)	min. 1, max. 99, mean 4.2
	Initial % Immobile	Initial percentage of immobile sperm in semen sample (excluding zeros)	min. 1, max. 39, mean 4.2 min. 1, max. 100, mean 58.7
	Volume (ml) SMR	Semen sample volume after sperm selection method (excluding zeros)	min. 0.04, max. 3.5, mean 0.3
	Concentration (M/ml) SMR	Sperm concentration after sperm selection method (excluding zeros)	min. 0.003, max. 204, mean 2.5
	Sperm motility Recovery / ml (M/ml)	Sperm motility recovery per volume after sperm selection method	min. 0.01, max. 167.3, mean 2.5
	Sperm motility Recovery (M)	Total sperm motility recovery after sperm selection method	min. 0.01. max. 1141.7. mean 3.7
	% Progressive	Percentage of progressive sperm after selection method	min. 1. max. 100. mean 81.3
	-		,
NDOMETRIAL (from pregnancy outcomes subset)	Protocol General	Endometrial Preparation Protocol (from pregnancy outcomes subset)	natural 71, semi-natural 1, HRT 1017, MNC 92, PN 8, PN + LPS 491
	OCP	Endometrial preparation priming using oral contraceptive pills	yes 45, no 1635
	FEMARA	Aromatase inhibitor used in preparation	yes 9, no 1671
	DECA	Decapeptyl used in preparation	yes 9, no 1671
	BUS		
		Buserelin used in preparation	yes 22, no 1658
	ANTA	Antagonist used in preparation	yes 136, no 1544
	BMI Female at ET	BMI measured at time of transfer	min. 13.1, max. 43.2, mean 27.2
	ET difficulty	Whether the transfer procedure was routine or experienced difficulty	routine 1665, difficult 15
	Endometrial Thickness	Measured thickness of endometrial lining	min. 3.9, max. 14.4, mean 8.0
	Vitrified twice	Embryo re-vitrified after thawing for biopsy	yes 36, no 1644
RANSFER			
RANSFER	N. embryos transferred	Number of embryos initially transferred	single 762, double 918

## Table 8. Clinical features extracted from the EHR data along with their definitions.

set based on both record integrity criteria and clinical exclusion criteria to obtain sequence-level blastocyst formation prediction dataset 2.B.1:

- First, we excluded 19,424 oocyte (43 patients, 97 treatments) records belonging to wells that had abnormal fertilization or didn't fertilize at all.
- We then excluded 3,272 oocyte (205 patients, 505 treatments) records belonging to slides that were clinically not useful, such as those belonging to test slides, or slides which are duplicated because a new id was generated after re-inserting the slide after removing embryo for biopsy, or embryos were not incubated for long enough due to regulatory and changing clinical best practice reasons.
- Next, we linked the oocyte records with the extracted imaging sequences, and excluded 366 oocyte (38 patients, 59 treatments) records that did not have a corresponding .pdb file.
- We also excluded 233 oocytes (21 patient, 39 treatments) with corrupted (for unknown reason) image records.
- After aligning images with corresponding EHR records we employ our image classifier, to detect invalid images, which includes: lack of embryo in frame, excessive artifacts, like air bubble that obstructs visibility and other

(refer to Section 4.B). We show samples of invalid images in Figure 3. We subsequently exclude continuous sequences of leading and trailing frames, marked as "invalid".

- Sequences containing 128 or fewer images after filtering are considered unusually short. This threshold was chosen based on the length of the shortest sequence that was deemed valid after manual review. Sequences that depict less than 96 hours of embryo development, based on the "hpi" feature of the last included image, are excluded as easy negatives. Additionally, we discard sequences with more than 15 marked images, after removing the leading and trailing images. The threshold for marked images was set at the 95th percentile, as the 96th percentile represented an abrupt increase, consisting of 30 empty images, leading to a disproportionate number of invalid observations. In total, this procedure excludes 2,321 embryos (89 patients, 166 treatments), amounting to 1,250,102 individual images.
- Additionally this process removes total of 1,019,404 images from the rest of 14,776 embryos (1,810 pa-

## tients, 2,500 treatments).


For the image-level development stage dataset (Section 2.B.2), we exclude sequences with potentially incomplete information about embryo development stages. This includes sequences where embryo annotations start later than the t2 stage, indicating a significant gap in the annotation of early development stages. We also remove sequences that lack development stage annotations or show a mismatch between stage annotations and EHR records, particularly where blastulation labels are missing despite indications of blastocyst formation in the EHR. Additionally, we exclude sequences labeled with the tDead stage, as these may lack complete stage labeling due to the embryo's non-viability for further transplantation. In total, this process removes 799 embryos (12 patients, 16 treatments) and 366,533 images.

For sequence-level genetic outcome prediction dataset 2.B.3, we apply additional filtering step to sequence-level blastocyst formation dataset, since we don't necessarily want to rely on stage annotations. Final dataset excludes 6,876 embryos (160 patients, 290 treatments) that did not undergo biopsy, and additional 28 embryos (1 patient, 4 treatments) for which biopsy was inconclusive. Which gives a total of 7,872 embryos (1,807 patients, 2,480 treatments).

For the sequence-level pregnancy outcome prediction dataset 2.B.4 we further filtered genetic outcome prediction dataset, by including only embryos which were selected for transfer, which excludes 6059 embryos (607 patients, 1020 treatments). Out of those selected for transfer 72 embryos (9 patients, 17 treatments), from those cryopreserved, did not survive warming. For outcome labels we exclude 61 (35 patients, 40 treatments) embryos without full set of results for all four labels, stemming from failure to follow up. Final dataset contains 1,680 embryos (998 patients, 1,129 treatments), which includes 71 embryos (46 patients, 47 treatments) transferred fresh and 1,609 embryos (966 patients, 1,086 treatments) transferred after cryopreservation, here we observe the overlap between patients and treatments in fresh and cryo transfers.

**Note:** In some cases, pregnancy outcome labels cannot be unambiguously determined when double embryo transfer is performed, but only one survives. In such situations, it is unclear which embryo should receive a positive or negative label. However, if neither embryo progresses to the next pregnancy stage, the samples can again be labeled without ambiguity. Rather than excluding embryos with uncertain outcomes, we leave the decision to the specific learning scheme used.

**4.B. Invalid image classification model.** To detect valid images, we trained a convolutional neural network to detect (i) wells with no embryo, (ii) images where the well is shifted substantially out of the image frame, (iii) images with excessive lighting artifacts such as low contrast or blurring, and (iv) images of embryos that drifted or grew out of the camera view field. Images of wells which do not contain an embryo occur when the camera for a given well is turned on before the embryo is inserted in the well or after the well is removed (for biopsy, cryopreservation or growth medium change). Due to clinic practices, the image sequences for all wells in each slide begin when at least one embryo is inserted, and end when the last embryo is removed. A continuous sequence of empty images in the end of frame sequence appears when one



**Fig. 3.** Examples of artifacts detected in the raw dataset: (a) a well which was misaligned with the camera, (b) an empty well, (c) An image which is excessively dark, and (d) a hatched blastocyst.

or more embryos are removed earlier than the final embryo in the slide. Embryos may also be inserted later when classic IVF or next-day ICSI technique is used, as fertilization occurs in a separate medium before the embryo is transferred to the EmbryoScope well, resulting in a continuous sequence of leading empty images. Fig. 3 illustrates examples of images which are classified as "invalid".

To train the classification network, we first created a dataset of 2,054 invalid and 11,325 valid image examples, identified through manual inspection. This dataset was then divided into training, validation, and test sets in a 60/20/20 ratio, with label stratification to ensure that each split maintains the original proportion of invalid to valid images.

**Note:** To preserve data integrity, we explicitly excluded all sequences used in training and/or evaluation of this model from the validation and test sets of the target dataset described in this report. This ensures that the validation and test results of downstream models are not influenced by any additional data purity.

We used these samples to train a ResNet-18 model with ImageNet weight initialization. We train model for 10 epochs, using Adam optimizer with a learning rate of 0.001. We use linear learning rate schedule with 1000 steps of warm up. To improve performance, we apply data augmentation techniques including random horizontal and vertical flip, and random cropping from  $250 \times 250$  to  $224 \times 224$ . We employ cropping to account for potential small shifts in embryo position, but not enough to introduce change of the label.

## 5. Conclusion

The ART Dataset is a real-world multimodal clinical dataset which combines detailed clinical features with high-resolution image time-series, to provide a rich source of information for analyzing fertility treatment outcomes and training machine learning models to automate labeling and clinical prediction

#### tasks.

- 1. Turchi P (2015) Prevalence, Definition, and Classification of Infertility in Clinical Management of
- Urch P (2013) Prevalence, belinition, and classification of mieriting in *Clinical management of Male Infertility*, eds. Cavallini G, Beretta G. (Springer International Publishing, Cham), pp. 5–11.
  Thirumalaraju P, et al. (2021) Evaluation of deep convolutional neural networks in classifying human embryo images based on their morphological quality. *Heliyon* 7(2):e06298.
  Meseguer M (2016) Time-lapse: the remaining questions to be answered. *Fertility and Sterility* 102(10):e0627.
- 105(2):295-296.
- 4. The HDF Group (2024) Hierarchical Data Format, version 5.